WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
1. (WO2012042540) ANTICANCER AGENT
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2012/042540    International Application No.:    PCT/IN2011/000680
Publication Date: 05.04.2012 International Filing Date: 30.09.2011
C12P 21/06 (2006.01), C12P 514/2
Applicants: AMRITA THERAPEUTICS LIMITED [--/IN]; c/o Ayurnet Health Care Ltd. 304 Regency Plaza, Near Rahul Tower Cross Roads, Satellite 380015 Ahmedabad (IN) (For All Designated States Except US).
SURI, Anil [IN/IN]; (IN) (For US Only).
KANOJIA, Deepika [IN/IN]; (IN) (For US Only).
SALUNKHE, Prabhakar [IN/IN]; (IN) (For US Only).
MAHALI, Sidharth [IN/IN]; (IN) (For US Only).
MANNA, Sunil Kumar [IN/IN]; (IN) (For US Only).
SUROLIA, Avadhesha [IN/IN]; (IN) (For US Only).
CHAKRABARTY, Ananda [US/US]; (US) (For US Only)
Inventors: SURI, Anil; (IN).
KANOJIA, Deepika; (IN).
SALUNKHE, Prabhakar; (IN).
MAHALI, Sidharth; (IN).
MANNA, Sunil Kumar; (IN).
SUROLIA, Avadhesha; (IN).
Agent: SHARMA, Rajashree; Corporate Law Group 1101-1104, 11th Floor, Kailash Building 26, Kasturba Gandhi Marg 110 001 New Delhi (IN)
Priority Data:
2754/MUM/2010 01.10.2010 IN
Abstract: front page image
(EN)The present invention thus provides microbial products as anticancer agents and pharmaceutical compositions comprising isolated and purified proteins or synthetic peptides, and methods of using them for the treatment of cancer. It is very important to develop new anticancer bioactive peptides having high activity and low toxicity; given that most currently available anticancer therapies either have significant toxicity, and/or are prone to development of resistance.
(FR)La présente invention concerne des produits microbiens utilisés comme agents anticancéreux et des compositions pharmaceutiques comprenant des protéines isolées et purifiées ou des peptides de synthèse, et des procédés d'utilisation de ceux-ci dans le traitement du cancer. Il est important de développer de nouveaux peptides biologiquement actifs anticancéreux présentant une activité élevée et une faible toxicité, étant donné que la plupart des thérapies anticancéreuses actuellement disponibles présentent une toxicité significative, et/ou sont sujettes au développement de résistances.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)